Aims Some reports have suggested that calcium channel blockers may be associated with an increased incidence of depression or suicide. There is a paucity of evidence from large scale studies. The aim of this study was to assess rates of depression with calcium channel antagonists using data from prescription event monitoring studies. Methods Observational studies on large cohorts of patients using lisinopril, enalapril (ACE inhibitors), nicardipine (type 2 calcium channel blocker) and diltiazem (type 3 calcium channel blocker) were conducted, using prescription-event monitoring. Rates of depression in the different drugs and rate ratios (95% CI) were computed. Results The crude overall rates of depression during treatment were 1.89, 1.92 and 1.62 per 1000 patient months for the ACE inhibitors, diltiazem and nicardipine, respectively. Using the ACE inhibitors as the reference group, the rate ratios for depression were 1.07 (0.82-1.40) and 0.86 (0.69-1.08) for diltiazem and nicardipine, respectively. Conclusions This study does not support the hypothesis that calcium channel blockers are associated with depression, when considering patients treated in general practice in the UK.
Introduction been described in full elsewhere [4] . It is essentially a hypothesis-generating technique. The following drugs, Calcium channel blockers are used for the treatment of ischaemic heart disease and hypertension, and are generally studied by this method, were included in this study: nicardipine (type 2 calcium channel blocker), diltiazem well tolerated. There have been some publications, however, suggesting that these drugs may be associated (type 3 calcium channel blocker), lisinopril and enalapril (angiotensin converting enzyme inhibitors). The studies with an increased incidence of depressive disorders and suicide [1, 2] , although another paper does not support were conducted between September 1984 and March 1989. These drugs were chosen because they were this [3] . We report the rates of depression and number of suicides from prescription-event monitoring studies on studied by PEM at approximately the same time, were indicated for cardiovascular problems, and had equivalent calcium channel blockers and angiotensin converting enzyme (ACE) inhibitors; we have computed rate ratios response rates to the PEM outcome questionnaire. They are therefore the most comparable drugs in the PEM to compare depression in patients receiving the two types of drug.
database. For comparison, we report crude event rates also for 38 other long-term use drugs (ranging from antiepileptics to proton pump inhibitors), studied by Methods PEM. The term depression was chosen for the main outcome, since there were sufficient events to allow Prescription-event monitoring (PEM) involves gathering information on symptoms or diagnoses (events) occurring meaningful statistical comparisons. This term includes any events written by the GP as 'depression', but also includes to patients after prescription of a study drug by general practitioners. Exposure and event (outcome) data on other events coded to 'depression', according to the system-organ dictionary developed for PEM. Examples approximately the first 10 000 patients on a newly of such events are neurotic depression, manic depression, postnatal depression and depressed mood. Thus the cohort were too low to allow valid statistical analysis, but The results in Table 3 show that depression is reported rather uncommonly, and that the rate shows little the numbers are reported. Outcome events occurring during treatment in the first 6 months were used as the difference between the drug groups. Thus the crude rate ratios for depression in the calcium channel blockers are numerator for the rates and rate ratios. Crude event rates for depression per 1000 patient months of treatment very close to, or equal to, one when compared to ACE inhibitors. Adjustment for potential confounders makes during the first month and during months 2-6, and the difference between the two (with 99% CI) were calculated very little difference to the rate ratios. from the PEM studies. Crude and adjusted rate ratios for the whole 6 month period were calculated: potential Discussion confounders were identified as age (categorized in In PEM studies, one type of 'signal' of a potential adverse quartiles), sex, season and indication (four categories: drug reaction (ADR) is represented by a difference ischaemic heart disease, hypertension, cardiac failure and between ID 1 and ID 2 where P<0.01. This is because others). The results were adjusted by Poisson regression typical type A ADRs tend to occur in the first month of models, using the statistical package Stata 5 (Statacorp, treatment, and the incidence then returns to a plateau Texas).
level (indicative of the background rate) during later months of treatment. The results from the PEM studies Results of these drugs did not generate such a 'signal' that depression was an ADR. Although this may indicate that The results from the PEM studies (see Table 1 ) show that the cohort sizes are large-in excess of 10 000 there was truly no ADR, there are other possible explanations: it could be due to the long latency of patients for each drug-and that the difference in rates of depression for month 1 and months 2-6 (ID 1 -ID 2 ) development of depression, or selective under-recording of depression, and it does not take into account any are not significantly different from 0 for any of the drugs. The number of suicides/suicide attempts is very low.
confounding factors. Therefore it was necessary to do a comparative study, in which adjusted rates of depression ID 1 of depression for 38 other long-term use drugs on the PEM database was 2.9 per 1000 patient months, and for the whole period of treatment were compared between drugs, and this comprises a comparatively simple ID 2 was 1.9 per 1000 patient months. These rates are very similar to those shown in Table 1 for the way of testing the hypothesis generated by other studies. This comparative study has not shown any evidence of selected drugs. Table 2 shows the summary characteristics of the an association between the diagnosis of depression and use of calcium channel blockers. cohorts, as used for the calculation of adjusted rate ratios. For the purposes of the calculation of the rate ratios, the It is possible that there is under-reporting of depression in our cohorts, either through nonresponse to the ACE inhibitor drugs have been combined, since there was no significant difference in the overall rates of questionnaires or due to incomplete records on the returned forms. Paykel [5] quotes a prevalence of 5% for depression between the two individual drugs. Although the age distribution of the cohorts is very similar between major depression and a further 5% for minor depression in consulters in general practice. However, it is widely the different drugs, there were significant differences between the sex distribution ( P<0.001), the predominant recognized that the diagnosis of depression is frequently missed in general practice, and even if it is recognized, it indication ( P<0.001), and the season of start of therapy ( P<0.001).
may not be recorded in the notes. Morbidity data from Table 3 Rates and rate ratios (ACE inhibitors as comparison group) for depression.
ACE inhibitors Diltiazem Nicardipine
Crude rate of depression* the General Practice Research Database [6] shows that preferentially to patients with a known diagnosis of depression. the prevalence of recorded depression in a single year varies between 1.2% and 1.7% of the population of
The putative association between calcium channel blockers and depression and suicide is contentious. 50-70 year olds, rates which agree with the data from the present study, where most of the patients were of Lindberg [1] suggested that suicide rates are related to use of calcium channel blockers. This was based on an this age. Thus although it is likely that depression is under-recorded in these data, this is not unexpected, and ecological study, which can only be considered hypothesis-generating, and on the results of a cohort study with is no worse than in another comparable GP database. Furthermore, there is no reason to suppose that this is wide confidence limits for the main outcome measure (relative risk for suicide of 5.4, 95% CI 1. 4-20.5 , among differential between the study drugs, and thus the rate ratios should give a true measure of effect. Equally, users of calcium channel blockers, vs nonusers). This cannot be considered as strong evidence, and no data although the response rate to the original mailing was about 60% in all the cohorts, and we have no estimate were presented for relative risk of depression in the cohort. The study by Hallas [2] on a large database of of the prevalence of depression in the nonresponders, it is unlikely that this would introduce a bias into the computerized prescription data from a County in Denmark, used a technique known as prescription calculation of rate ratios. The rates of depression in the 38 other long-term use drugs on the PEM database do sequence symmetry. The aim was principally to look for any association between b-adrenoceptor blockers and not suggest that there is any particular reporting bias in the selected, cardiovascular, drugs. The calendar periods depression, but he also analysed the data from other cardiovascular drugs. This study showed no association during which data were collected varied between the drugs under study (between 1984 and 1989) , but there is between b-adrenoceptor blockers and depression, but a depression-provoking effect for the ACE-inhibitor enalaconsiderable overlap between the calcium channel blockers and the ACE inhibitors. This study is unable to pril, rate ratio 1.35, 95% CI 1.03-1.80 (although not for captopril), and for the calcium channel blocker diltiazem, differentiate between incident and chronic cases of depression, but this should not matter, since there is no rate ratio 1.26, 95% CI 1.14-2.00 (although not for verapamil or nifedipine). The technique used in this particular reason for one type of drug to be given We would like to record our keen appreciation of the co-operation study was essentially a screening tool for adverse drug of general practitioners in England in the conduct of PEM studies.
reactions and was open to confounding by indication, We would also like to thank the Prescription Pricing Authority even though the author attempted to control for this.
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